CD8 cell

(redirected from CD8+ cell)
Also found in: Dictionary, Thesaurus.
Related to CD8+ cell: Cytotoxic T lymphocytes

CD8 cell

a T lymphocyte that secretes large amounts of gamma-interferon, a lymphokine involved in the body's defense against viruses. CD8 cells prevent the unnecessary formation of antibodies. Also called cytotoxic T cell. See also CD4.

CD8 cell, CD8+ cell

a major classification of T lymphocytes, referring to those that carry the CD8 antigen; the major subtypes are the cytotoxic T lymphocytes and the suppressor cells. Also called CD8 T lymphocytes.

CD8 cell

A suppressor T cell, e.g., a cytotoxic T cell.
See also: cell
References in periodicals archive ?
CD8+ cells were mainly located inside and under the epithelium whereas CD4+ cells were scattered in the autologous matrix.
Thus increased receptor expression of CD95+ was found in CD4+, CD8+ cells and natural killers, both CD16+ and CD56+ cells.
Biopsies' analyses revealed that there is a higher number of macrophages than CD8+ cells in pleural tissue inflammation.
The correlation between the number of granulomas and CD68+ or CD8+ cells counts is shown in Fig.
The antiviral capacity of these virus-specific CD8+ cells is strongly dependent on their ability to migrate and localize to the lungs and infected airway epithelium (14), where they appear 5-7 days after infection (15).
In the mean values of the subgroups of CD4+ and CD8+ cells and in the ratio CD4+ : CD8+ cells no significant changes occurred in the verum and placebo periods.
These extra cells must be removed by activated CD8+ cells.
The research, presented at the Gordon Research Conference "The Biology of Aging" in Ventura, California, demonstrated that the telomerase activators not only increased the proliferative capacity of cytotoxic (CD8+) T-cells and their ability to produce a virus-fighting molecule, gamma Interferon (IFN(gamma)), but also improved the ability of CD8+ cells from HIV-positive donors to inhibit virus production in infected CD4+ T-cells.
15, 2016, issue of the Journal of Clinical Investigation, the research team analyzed tumors from 40 patients, and found that the relative size of a population of T cells known as partially exhausted CD8+ cells in the tumors accurately predicted most patients' responses to immunotherapy drugs that target a protein called PD-1.
The collaboration combines OHSU's outstanding research and expertise to isolate and clone CD8+ cells from latent TB patients with JPT's proprietary SPOT(TM) technology to produce very large numbers of peptides.
Recently, Geron's collaborators at UCLA presented results that indicate that both GRN139951 and GRN140665 stimulated gamma Interferon production, proliferation and cytolytic activity of CD8+ cells (cytotoxic T-lymphocytes) from HIV/AIDS donors.
There are also a number of Isolex(R) systems currently in use in investigational protocols for gene therapy and dendritic cell therapy, engineered transplants with alternative donors and for autoimmune diseases, and depletion of specific T-cell subsets such as CD4+ or CD8+ cells.